1
|
Coelho FS, Oliveira MM, Vieira DP, Torres PHM, Moreira ICF, Martins-Duarte ES, Gonçalves IC, Cabanelas A, Pascutti PG, Fragoso SP, Lopes AH. A novel receptor for platelet-activating factor and lysophosphatidylcholine in Trypanosoma cruzi. Mol Microbiol 2021; 116:890-908. [PMID: 34184334 DOI: 10.1111/mmi.14778] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 06/24/2021] [Accepted: 06/26/2021] [Indexed: 01/12/2023]
Abstract
The lipid mediators, platelet-activating factor (PAF) and lysophosphatidylcholine (LPC), play relevant pathophysiological roles in Trypanosoma cruzi infection. Several species of LPC, including C18:1 LPC, which mimics the effects of PAF, are synthesized by T. cruzi. The present study identified a receptor in T. cruzi, which was predicted to bind to PAF, and found it to be homologous to members of the progestin and adiponectin family of receptors (PAQRs). We constructed a three-dimensional model of the T. cruzi PAQR (TcPAQR) and performed molecular docking to predict the interactions of the TcPAQR model with C16:0 PAF and C18:1 LPC. We knocked out T. cruzi PAQR (TcPAQR) gene and confirmed the identity of the expressed protein through immunoblotting and immunofluorescence assays using an anti-human PAQR antibody. Wild-type and knockout (KO) parasites were also used to investigate the in vitro cell differentiation and interactions with peritoneal mouse macrophages; TcPAQR KO parasites were unable to react to C16:0 PAF or C18:1 LPC. Our data are highly suggestive that PAF and LPC act through TcPAQR in T. cruzi, triggering its cellular differentiation and ability to infect macrophages.
Collapse
Affiliation(s)
- Felipe S Coelho
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Mauricio M Oliveira
- Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | | | - Pedro H M Torres
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Isabel C F Moreira
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Erica S Martins-Duarte
- Departmento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Inês C Gonçalves
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Adriana Cabanelas
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Pedro G Pascutti
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Stenio P Fragoso
- Laboratório de Biologia Molecular e Sistêmica de Tripanossomatídeos, Instituto Carlos Chagas, Curitiba, Brazil
| | - Angela H Lopes
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| |
Collapse
|
3
|
Gazos-Lopes F, Oliveira MM, Hoelz LVB, Vieira DP, Marques AF, Nakayasu ES, Gomes MT, Salloum NG, Pascutti PG, Souto-Padrón T, Monteiro RQ, Lopes AH, Almeida IC. Structural and functional analysis of a platelet-activating lysophosphatidylcholine of Trypanosoma cruzi. PLoS Negl Trop Dis 2014; 8:e3077. [PMID: 25101628 PMCID: PMC4125143 DOI: 10.1371/journal.pntd.0003077] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2013] [Accepted: 06/13/2014] [Indexed: 12/15/2022] Open
Abstract
Background Trypanosoma cruzi is the causative agent of the life-threatening Chagas disease, in which increased platelet aggregation related to myocarditis is observed. Platelet-activating factor (PAF) is a potent intercellular lipid mediator and second messenger that exerts its activity through a PAF-specific receptor (PAFR). Previous data from our group suggested that T. cruzi synthesizes a phospholipid with PAF-like activity. The structure of T. cruzi PAF-like molecule, however, remains elusive. Methodology/Principal findings Here, we have purified and structurally characterized the putative T. cruzi PAF-like molecule by electrospray ionization-tandem mass spectrometry (ESI-MS/MS). Our ESI-MS/MS data demonstrated that the T. cruzi PAF-like molecule is actually a lysophosphatidylcholine (LPC), namely sn-1 C18:1(delta 9)-LPC. Similar to PAF, the platelet-aggregating activity of C18:1-LPC was abrogated by the PAFR antagonist, WEB 2086. Other major LPC species, i.e., C16:0-, C18:0-, and C18:2-LPC, were also characterized in all T. cruzi stages. These LPC species, however, failed to induce platelet aggregation. Quantification of T. cruzi LPC species by ESI-MS revealed that intracellular amastigote and trypomastigote forms have much higher levels of C18:1-LPC than epimastigote and metacyclic trypomastigote forms. C18:1-LPC was also found to be secreted by the parasite in extracellular vesicles (EV) and an EV-free fraction. A three-dimensional model of PAFR was constructed and a molecular docking study was performed to predict the interactions between the PAFR model and PAF, and each LPC species. Molecular docking data suggested that, contrary to other LPC species analyzed, C18:1-LPC is predicted to interact with the PAFR model in a fashion similar to PAF. Conclusions/Significance Taken together, our data indicate that T. cruzi synthesizes a bioactive C18:1-LPC, which aggregates platelets via PAFR. We propose that C18:1-LPC might be an important lipid mediator in the progression of Chagas disease and its biosynthesis could eventually be exploited as a potential target for new therapeutic interventions. Chagas disease, caused by the parasite Trypanosoma cruzi, was exclusively confined to Latin America but it has recently spread to other regions of the world. Chagas disease affects 8–10 million people and kills thousands of them every year. Lysophosphatidylcholine (LPC) is a major bioactive phospholipid of human plasma low-density lipoproteins (LDL). Platelet-activating factor (PAF) is a phospholipid similar to LPC and a potent intercellular mediator. Both PAF and LPC have been reported to act on mammalian cells through PAF receptor (PAFR). Previous data from our group suggested that T. cruzi produces a phospholipid with PAF activity. Here, we describe the structural and functional analysis of different species of LPC from T. cruzi, including a LPC with a fatty acid chain of 18 carbon atoms and one double bond (C18:1-LPC). We also show that C18:1-LPC is able to induce rabbit platelet aggregation, which is abrogated by a PAFR antagonist. In addition, a three-dimensional model of human PAFR was constructed. Contrary to other T. cruzi LPC molecules, C18:1-LPC is predicted to interact with the PAFR model in a fashion similar to PAF. Further studies are needed to validate the biosynthesis of T. cruzi C18:1-LPC as a potential drug target in Chagas disease.
Collapse
Affiliation(s)
- Felipe Gazos-Lopes
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
| | - Mauricio M. Oliveira
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Lucas V. B. Hoelz
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco G, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Danielle P. Vieira
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Alexandre F. Marques
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Departamento de Parasitologia, Pampulha, Belo Horizonte, Minas Gerais, Brazil
| | - Ernesto S. Nakayasu
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
| | - Marta T. Gomes
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
- Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco H, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Nasim G. Salloum
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
| | - Pedro G. Pascutti
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco G, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Thaïs Souto-Padrón
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Robson Q. Monteiro
- Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco H, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
| | - Angela H. Lopes
- Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Cidade Universitária, Centro de Ciências da Saúde, Bloco I, Ilha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil
- * E-mail: (AHL); (ICA)
| | - Igor C. Almeida
- The Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso (UTEP), El Paso, Texas, United States of America
- * E-mail: (AHL); (ICA)
| |
Collapse
|
4
|
Trypanosoma cruzi heparin-binding proteins mediate the adherence of epimastigotes to the midgut epithelial cells of Rhodnius prolixus. Parasitology 2012; 139:735-43. [PMID: 22310218 DOI: 10.1017/s0031182011002344] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Heparin-binding proteins (HBPs) have been demonstrated in both infective forms of Trypanosoma cruzi and are involved in the recognition and invasion of mammalian cells. In this study, we evaluated the potential biological function of these proteins during the parasite-vector interaction. HBPs, with molecular masses of 65·8 kDa and 59 kDa, were isolated from epimastigotes by heparin affinity chromatography and identified by biotin-conjugated sulfated glycosaminoglycans (GAGs). Surface plasmon resonance biosensor analysis demonstrated stable receptor-ligand binding based on the association and dissociation values. Pre-incubation of epimastigotes with GAGs led to an inhibition of parasite binding to immobilized heparin. Competition assays were performed to evaluate the role of the HBP-GAG interaction in the recognition and adhesion of epimastigotes to midgut epithelial cells of Rhodnius prolixus. Epithelial cells pre-incubated with HBPs yielded a 3·8-fold inhibition in the adhesion of epimastigotes. The pre-treatment of epimastigotes with heparin, heparan sulfate and chondroitin sulfate significantly inhibited parasite adhesion to midgut epithelial cells, which was confirmed by scanning electron microscopy. We provide evidence that heparin-binding proteins are found on the surface of T. cruzi epimastigotes and demonstrate their key role in the recognition of sulfated GAGs on the surface of midgut epithelial cells of the insect vector.
Collapse
|